Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.

Volz, Barbara; Schmidt, Manuel; Heinrich, Kerstin; Kapp, Kerstin; Schroff, Matthias; Wittig, Burghardt

Volz, Barbara; Schmidt, Manuel; Heinrich, Kerstin; Kapp, Kerstin; Schroff, Matthias; Wittig, Burghardt.

Afiliação

Volz B; Foundation Institute for Molecular Biology and Bioinformatics, Freie Universitaet Berlin, Berlin, Germany; Mologen AG, Berlin, Germany.
Schmidt M; Mologen AG , Berlin, Germany.
Heinrich K; Foundation Institute for Molecular Biology and Bioinformatics, Freie Universitaet Berlin, Berlin, Germany; Mologen AG, Berlin, Germany.
Kapp K; Mologen AG , Berlin, Germany.
Schroff M; Mologen AG , Berlin, Germany.
Wittig B; Foundation Institute for Molecular Biology and Bioinformatics, Freie Universitaet Berlin , Berlin, Germany.

Mol Ther Oncolytics ; 3: 15023, 2016.

Article em En | MEDLINE | ID: mdl-27119114

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Mol Ther Oncolytics Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google